

# ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC) Triple Negative Breast Cancer Hepatocellular Carcinoma (HCC) Bladder Cancer

## A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT03232593 ML39313

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### ***Trial Summary:***

This Phase 4, prospective, multicenter, non-interventional, regulatory post-marketing surveillance study will collect information on the the safety and effectiveness of atezolizumab under the clinical practice, and update the drug label approved by the MFDS in Korea.

**Hoffmann-La Roche**

Sponsor

Phase

---

**NCT03232593 ML39313**

Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
All

**Healthy Volunteers**  
No

---